Clinical Trials Browser

Interventional × Has announcements × vorasidenib × Clear all

NCT04164901 2025-04-03

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Phase 3 Active not recruiting

331 enrolled 25 charts 1 FDA

Glioma